Friday, April 26, 2019
Genprex (GNPX)
Poised to Emerge as a Leader in Cancer Gene Therapy.
Genprex Inc is a US-based clinical stage gene therapy company. It is engaged in developing a new approach to treating cancer, based upon its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy.
Cosme Ordoñez, M.D., Ph. D. , Life Sciences Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Coverage
Initiation. We are initiating coverage of Genprex, Inc. with an
Outperform Rating and a $5.00 target price. - Unique Gene
Therapy Technology. We believe that Genprex will emerge as a leader in the area
of gene therapy for the treatment of cancer. The Company is developing a unique
platform technology consisting on the use of lipid nano…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.